VivoSeq
Psychiatry

Alcohol Dependence

110

Pipeline Programs↗

4

Active Trials↗

46

Companies Involved↗

Alcohol Dependence is a highly competitive landscape with 110 programs across 46 companies. The most active players are Catalyst Biosciences, Eli Lilly, Merck & Co.. 47 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

11/100

Mech. Concentration

4/100

Completion Rate

87/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Catalyst Biosciences

1 program

Phase 1Eli Lilly logo

Eli Lilly

2 programs

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2V

Vyne Therapeutics Inc.

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2H

Harmony Biosciences Management, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical8

Diazepam

Akero Therapeutics

Sulfasalazine

Pfizer

Relacorilant

Corcept Therapeutics

Nalmefene Hydrochloride Hydrate

Otsuka

Thiopental

Abbott

Phase 17

Perampanel

Catalyst Biosciences

Saracatinib

National Cancer Institute (NCI)

Doxazosin

Viatris Specialty LLC

Desacyl Ghrelin

Imperial College London

Ketalar

Helse Møre og Romsdal HF

Phase 235

Exenatide

AstraZeneca

Suvorexant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ketamine Hydrochloride

Boehringer Ingelheim

Citicoline

University of Texas Southwestern Medical Center

Pitolisant

Harmony Biosciences Management, Inc.

Phase 313

Alcohol

Astellas

Olanzapine

MODAG GmbH

Calcium Carbonate

Otsuka

Divalproex Sodium

Teva

Bupropion

Glaxo Dba Glaxosmithkline

Approved47

Lacosamide

UCB

Topiramate

Wim Janssens

Tolcapone

Bausch Health Americas, Inc.

Brexpiprazole

Otsuka

Fenofibrate

Jagotec

Analysis

Modality Breakdown

98%

Small molecule

114 of 116 classified programs — the dominant modality here.

2%ALL OTHERSPeptide22%

Small molecule leads; the ring shows all 116 classified programs, each share of the total. Modality classified for 100% of 117 pipeline programs.

Analysis

Trial Status

113

clinical trials

Completed88 · 78%
Terminated10 · 9%
Unknown status8 · 7%
Recruiting4 · 4%
Withdrawn3 · 3%

Clinical Trials

Trial Activity

113 trials

A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence
Recruiting·—·Phase 2·NCT06845124·150 enrolled
Behavioral and Functional Task Development, Implementation, and Testing
Recruiting·National Institute on Alcohol Abuse and Alcoholism (NIAAA)·Preclinical·NCT02108054·400 enrolled
Characterization Imaging Instruments for Addiction Neuroimaging Assessments
Recruiting·National Institute on Alcohol Abuse and Alcoholism (NIAAA)·N/A·NCT02108080·1,000 enrolled
Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence
Recruiting·CCharite University, Berlin, Germany·Preclinical·NCT07388693·20 enrolled
Efficacy and Safety of High Dose Baclofen for Alcohol Dependence
Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01980706·120 enrolled
Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence
Completed·Otsuka logoOtsuka·N/A·NCT04107051·533 enrolled
Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone
Completed·MMedical University of South Carolina·Phase 3·NCT00183196·150 enrolled
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
Completed·AAnders Fink-Jensen, MD, DMSci·Phase 2·NCT03232112·152 enrolled
Efficacy of Nalmefene in Patients With Alcohol Dependence
Completed·Lundbeck logoLundbeck·Phase 3·NCT00811720·598 enrolled
A New Pharmacotherapy for Alcohol Dependence: Olanzapine
Completed·TThe Mind Research Network·Phase 3·NCT00746785·304 enrolled
Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence
Completed·—·Phase 2·NCT00142818·164 enrolled
Varenicline For Smokers In Recovery From Alcohol Dependence
Completed·MMayo Clinic·Phase 2/3·NCT01092702·32 enrolled
Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.
Completed·UUniversity of Pennsylvania·Phase 3·NCT00124059·61 enrolled
ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence
Completed·AAlkermes, Inc.·Phase 2·NCT00981617·406 enrolled
Prazosin Alcohol Dependence IVR Study
Completed·UUniversity of Washington·Phase 4·NCT00167687·23 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)